Opinion: What defines high-risk CLL in the post-chemoimmunotherapy era?
| Autoři | |
|---|---|
| Rok publikování | 2023 |
| Druh | Článek v odborném periodiku |
| Časopis / Zdroj | Frontiers in Oncology |
| Fakulta / Pracoviště MU | |
| Citace | |
| www | https://www.frontiersin.org/articles/10.3389/fonc.2023.1106579/full |
| Doi | http://dx.doi.org/10.3389/fonc.2023.1106579 |
| Klíčová slova | chronic lymphocytic leukemia (CLL); high-risk; TP53; definition; BTK - Bruton's tyrosine kinase; BCL2 (B-cell lymphoma 2); COVID-19; risk factor |
| Přiložené soubory | |
| Popis | The definition of high-risk chronic lymphocytic leukemia (CLL) was relatively simple in the chemoimmunotherapy era, as it was defined by only one genomic marker, TP53 alteration, along with poor responses to purine-analogue based treatment. While other biomarkers such as unmutated IGHV, del(11q), high ZAP70 expression and high CD38 expression were associated with inferior prognosis, TP53 deficiency by mutation and/or del(17p) remained the only biomarker that clearly guided treatment decisions. |
| Související projekty: |